LAUSR

OBJECTIVE To evaluate the safety and the serological response after two doses of mRNA-based SARS-CoV-2 vaccination in people living with HIV (PLWH). PATIENTS AND METHODS Participants were evaluated four weeks after the second dose of mRNA-1273 or BNT162b2 vaccine. Tolerability was evaluated with a specific adverse event questionnaire. Patient's sera were analyzed using LIAISON® SARS-CoV-2 TrimericS IgG (DiaSorin). RESULTS One-hundred PLWH were included, 75% of them men, with a mean age of 44 ± 11 years old, all receiving antiretroviral treatment and mostly with controlled viral loads (98% with HIV RNA <50 copies/mL) and 96% had >200 CD4/μL. All patients seroconverted after vaccination (antibody concentration ≥33.8 BAU/mL). Only 3% of the patients had a low antibody concentration (<520 BAU/mL), whereas a 67% of them had concentrations above the assay's detection range (>2,080 BAU/mL). Fifty-six patients had local or systemic symptoms, being mild arthromyalgia the most common systemic symptom. No severe adverse events were reported. CONCLUSIONS vaccination with two doses of mRNA-1273 or BNT162b2 is safe in PLWH under effective ART and it leads to a successfully antibodies response.